Get the Stockscreener App
1.39
4.79%
-0.07
Pre-market:
1.36
-0.03
-2.16%
Acumen Pharmaceuticals Inc stock is traded at $1.39, with a volume of 343.60K.
It is down -4.79% in the last 24 hours and down -11.46% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.46
Open:
$1.4
24h Volume:
343.60K
Relative Volume:
0.77
Market Cap:
$84.20M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.2411
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-1.42%
1M Performance:
-11.46%
6M Performance:
+10.32%
1Y Performance:
-50.53%
1-Day Range:
$1.39
$1.4253
1-Week Range:
$1.35
$1.60
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.39 | 88.44M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Will Acumen Pharmaceuticals Inc. rebound enough to break evenInsider Buying & Low Risk Entry Point Guides - Newser
Market reaction to Acumen Pharmaceuticals Inc.’s recent newsMarket Trend Summary & Growth Focused Entry Reports - Newser
Can you recover from losses in Acumen Pharmaceuticals Inc.Layoff News & Community Consensus Stock Picks - Newser
Applying Wyckoff theory to Acumen Pharmaceuticals Inc. stockJuly 2025 Big Picture & Growth-Oriented Investment Plans - Newser
Acumen Pharmaceuticals Inc. stock outlook for YEARWatch List & Verified Technical Trade Signals - Newser
Evaluating Acumen Pharmaceuticals Inc. with trendline analysis2025 Top Gainers & Community Verified Swing Trade Signals - Newser
Visual trend scoring systems applied to Acumen Pharmaceuticals Inc.Weekly Trade Recap & Verified Momentum Watchlists - Newser
Volume spikes in Acumen Pharmaceuticals Inc. stock – what they meanStop Loss & High Accuracy Trade Signal Alerts - Newser
What institutional flow reveals about Acumen Pharmaceuticals Inc.2025 Volatility Report & Fast Exit and Entry Trade Guides - Newser
What machine learning models say about Acumen Pharmaceuticals Inc.Quarterly Performance Summary & Precise Entry and Exit Recommendations - Newser
Published on: 2025-08-27 10:50:07 - Newser
How high can Acumen Pharmaceuticals Inc. stock go2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Developing predictive dashboards with Acumen Pharmaceuticals Inc. dataWeekly Gains Report & Free Community Consensus Stock Picks - Newser
What’s the recovery path for long term holders of Acumen Pharmaceuticals Inc.Earnings Overview Report & Reliable Intraday Trade Plans - Newser
Can machine learning forecast Acumen Pharmaceuticals Inc. recoveryWeekly Trade Report & Low Risk High Reward Trade Ideas - Newser
Is this a good reentry point in Acumen Pharmaceuticals Inc.Weekly Profit Report & Technical Buy Zone Confirmations - Newser
Will Acumen Pharmaceuticals Inc. price bounce be sustainableMarket Movers & Low Drawdown Momentum Trade Ideas - Newser
Technical analysis overview for Acumen Pharmaceuticals Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - Newser
Using data tools to time your Acumen Pharmaceuticals Inc. exitTreasury Yields & Low Drawdown Trading Techniques - Newser
How to build a dashboard for Acumen Pharmaceuticals Inc. stockEarnings Recap Summary & Daily Stock Momentum Reports - Newser
Can Acumen Pharmaceuticals Inc. recover in the next quarterWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Leading Alzheimer's Therapeutic Developer Acumen Pharmaceuticals Announces Key September Investor Events - Stock Titan
Tick level data insight on Acumen Pharmaceuticals Inc. volatilityEarnings Trend Report & AI Enhanced Trading Alerts - Newser
Should you wait for a breakout in Acumen Pharmaceuticals Inc.Recession Risk & Weekly High Potential Alerts - Newser
Acumen Pharmaceuticals shares rise 2.58% premarket after Boogie Beckman's AI innovations. - AInvest
Advanced analytics toolkit walkthrough for Acumen Pharmaceuticals Inc.2025 Investor Takeaways & Consistent Growth Stock Picks - Newser
Will Acumen Pharmaceuticals Inc. benefit from macro trendsMarket Activity Report & Low Risk Growth Stock Ideas - Newser
Update Recap: Is Acumen Pharmaceuticals Inc. a play on infrastructure spending2025 Investor Takeaways & Technical Pattern Alert System - sundaytimes.kr
Aug Reactions: Can Acumen Pharmaceuticals Inc. sustain its profitabilityMarket Volume Summary & Weekly Top Performers Watchlists - sundaytimes.kr
Quarterly Recap: Is Acumen Pharmaceuticals Inc. stock good for income investorsStop Loss & Target Return Focused Stock Picks - theviewers.co.kr
What dividend growth rate does Acumen Pharmaceuticals Inc. offer2025 Volatility Report & Daily Stock Trend Reports - theviewers.co.kr
Bullish Candlestick Pattern Forms in Acumen Pharmaceuticals Inc.Quarterly Trade Summary & Weekly Top Performers Watchlists - mustnews.co.kr
Quant Funds Rotate Into Acumen Pharmaceuticals Inc. StockWeekly Profit Summary & Fast Moving Stock Trade Plans - sundaytimes.kr
Is Acumen Pharmaceuticals Inc. exposed to political riskRisk Management & Reliable Momentum Entry Alerts - theviewers.co.kr
Acumen Pharmaceuticals Inc. stock momentum explainedWeekly Investment Recap & Smart Investment Allocation Tips - Newser
What Technical Tools Say About Acumen Pharmaceuticals Inc. RecoveryTrade Analysis Summary & Weekly Setup with High ROI Potential - newsyoung.net
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):